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The International Society of Nephrology (ISN) Forefronts
Symposium ‘Induction and Resolution of Renal Inflammation’
took place in May 2010 on the Island of Sylt, Germany.
The program included basic and clinical aspects of
inflammation with a special focus on human and
experimental glomerulonephritis. Distinguished scientists
from different fields of inflammation research reported their
recent discoveries and discussed emerging topics including
the role of resolution for inflammatory processes; the ‘new
and old’ cellular players of innate immunity and their
mediators; the fundamental role of T-cell subtypes and
chemokines; new aspects of B cell-mediated immune
responses; and finally the potential implication of results
from basic science for human inflammatory renal disease.
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Inflammation is the complex biological response of the
immune system to a great variety of harmful stimuli. This
process of tightly controlled cellular and biochemical events
has evolved to eliminate invading pathogens, remove
damaged or abnormal cells, and preserve tissue integrity.
Impaired self-tolerance and uncontrolled activation of
the immune system can result in deleterious inflammatory
responses, ultimately leading to autoimmune disease.
Inflammatory renal disease develops when uncontrolled
immune activation directly targets kidney antigens, as in
anti-glomerular basement membrane disease and membra-
nous nephropathy, or when systemic autoimmunity involves
kidney structures, as in small-vessel vasculitis or systemic
lupus. Production of proinflammatory cytokines and chemo-
kines by resident kidney cells and infiltrating leukocytes
initiate and perpetuate the inflammatory process, resulting in
tissue damage and loss of renal function.
In the past decades, extensive studies on the molecular
signaling pathways that initiate the inflammatory cascade
and recruit immune cells to the site of inflammation have
identified critical mediators in this process. Contrariwise, the
mechanisms that downregulate inflammation and switch the
immune response toward resolution remain only incomplete-
ly understood. Recent studies indicate that the resolution
of inflammation is an active process requiring activation
of endogenous signaling pathways that counter-regulate
the inflammatory response. Understanding the molecular
requirements for resolution may facilitate the development of
drugs that can be used to resolve unwanted inflammation in
acute (and chronic) inflammatory conditions in humans.
This report describes the highlights from the International
Society of Nephrology (ISN) 2010 Forefronts Symposium
‘Induction and Resolution of Renal Inflammation,’ which
took place from 06 to 09 May 2010 in Sylt (Germany).
RESOLUTION OF INFLAMMATION
Dr Derek W. Gilroy (University of London, UK) gave an
overview of this emerging field in the keynote lecture
‘Resolution of inflammation: state of the art, definition and
terms.’ He provided details of how the study of resolution in
acute and chronic inflammation might help in developing
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novel anti-inflammatory therapeutics, and defined key terms
and components of interest in the resolution process.1
Dr. Gilroy discussed his recent work on cyclooxygenase and
lipoxygenase-derived lipid mediators (cyclopentenone pros-
taglandins, prostaglandin D2, lipoxins, and aspirin-triggered
epi-lipoxins) that limit the continuity of inflammatory
responses. He furthermore addressed the current under-
standing of cellular players in this setting and introduced
some new soluble mediators (resolvins) and their receptors as
novel, potentially pro-resolving agents.2
Dr Adriano G. Rossi (University of Edinburgh, UK)
addressed the importance of apoptosis for clearance of
potentially injurious inflammatory cells, such as neutrophils,
and highlighted the role of apoptosis for efficient resolution
of inflammation. Subsequently, he discussed novel strategies
for termination of deleterious inflammatory responses with a
special focus on translation of these strategies into pro-
resolution therapies.3
Dr Jeremy Hughes (University of Edinburgh, UK) provided
an overview of the function of inflammatory cells in renal
repair and resolution with a special focus on neutrophils and
monocytes/macrophages.4 More specifically, he discussed the
basic mechanisms involved in the potential partnership of
neutrophils and macrophages during time course of the
inflammatory response. Finally, he highlighted that apoptotic
neutrophils are capable of reducing tissue damage by
releasing soluble factors (for example, a-defensins) that can
inactivate lipopolysaccharide-stimulated macrophages.5
Dr David C. Harris (University of Sydney, Australia)
discussed the pro- and anti-inflammatory roles of macro-
phages in renal inflammation. Macrophage infiltration is a
morphological hallmark of human and experimental chronic
kidney disease. The degree of macrophage infiltration
correlates with the severity of injury, suggesting a causal
link. However, macrophages are a heterogeneous population
of cells, some of which are proinflammatory and pathogenic
(M1) and others that are anti-inflammatory and protective
(M2a-c types).6 M2-programmed macrophages prepared
ex vivo and transferred into recipient mice with inflammatory
renal disease have been shown to ameliorate tissue injury by
modulating effector functions of pathogenic macrophages
and T cells in the kidney.7 Before these phenotypically diverse
cells could be used as a therapeutic tool for human kidney
disease, the understanding of macrophage biology has to be
improved by further studies.
INNATE IMMUNE RESPONSE: NEW AND OLD CELLULAR
PLAYERS AND MEDIATORS
Two sessions focused on aspects of the innate immune
response. These included the classical players of innate
immunity (neutrophils, complement factors, and the Toll-
like receptor (TLR) family), as well as innate cell types that
have just recently attracted attention in experimental nephro-
logy, namely basophilic granulocytes, mast cells, natural killer
T cells, and dendritic cells (DCs). The speakers provided
mechanistic insight into recently discovered functions of
these cells in basic immunology and experimental models of
nephritis.
In his talk, ‘New insight in the role of basophils in
immune regulation,’ Dr Matthias Mack (University of
Regensburg, Germany) highlighted recent technical advances
that permit detection and analysis of these rare cells in
patients and in murine disease models. Taking advantage of
these techniques, his group recently demonstrated that
basophils are important contributors to humoral memory
immune responses. The basophil-dependent effects on B cells
required interleukins 6 and 4 (IL-6 and IL-4), and increased
the capacity of CD4þ T cells to provide B-cell help.8 These
findings shed new light on the pathogenesis of antibody-
mediated diseases and may have an impact on vaccine
development.
Dr Stephen Holdsworth (Monash University, Melbourne,
Australia) provided an overview about the role of mast cells
in autoimmune disease and glomerulonephritis. Mast cells
are involved in allergy and anaphylaxis, as well as in the
defense against pathogens. Recently, mast cells have been
suggested to participate also in human renal disease;9
however, their exact functional role remains to be defined.
In mast cell-deficient Wsh mice, autoimmune anti-myeloper-
oxidase (MPO)-mediated glomerulonephritis was signifi-
cantly enhanced, as was autoimmunity to MPO compared
with wild-type mice. These data suggest that mast cells may
maintain peripheral tolerance to the vasculitis-associated
autoantigen MPO.
Dr Christian Kurts (University of Bonn, Germany)
introduced a new concept of DC-mediated cytotoxic
T lymphocyte activation. Specialized DCs induce cytotoxic
T lymphocyte responses against extracellular antigens, such
as viruses, bacteria, or vaccines, using a mechanism termed
cross-priming.10 DCs require cognate ‘licensing’ for cross-
priming that denotes stimulatory signals from T helper (Th)
cells that switch the DCs into a functional state capable of
immunogenic T-cell priming. This is called ‘classical cross-
priming.’ Dr Kurts demonstrated an alternative mechanism
of cognate licensing by the so-called natural killer T cells that
recognize lipid instead of peptide antigens.11 These findings
have relevance for basic immunology, showing that DCs can
be licensed for cross-priming by natural killer T or Th cells,
depending on the type of antigen they encounter. Natural
killer T and Th cells use at least two independent chemokine
pathways (chemokine (C-C motif) receptor 4 and 5 (CCR4
and CCR5)) to attract naive cytotoxic T lymphocytes that
acted synergistically and may be exploited to improve
vaccinations.11
Dr Stephan Segerer (University of Zu¨rich, Switzerland)
provided an overview of the role of DCs in human
glomerulonephritis. Descriptions of cells with dendritic
morphology in rodent kidneys date back to the early 1970s.
During the 1980s and 1990s, HLA-DR-positive DCs were
found to be localized in normal renal tissue and in the inter-
stitium from patients with glomerulonephritis.12,13 Numer-
ous recent experimental studies revealed their involvement in
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models of renal injury, for example, their ability to capture
and present glomerular antigens to kidney-infiltrating
Th cells.14 Th cells responded with cytokine and chemo-
kine production that attracted immune effector cells that
drive nephritis progression. The functional role of different
DC subtypes in human kidneys has still to be fully elucidated.
Dr Eicke Latz (University of Bonn, Germany) introduced
the recently described innate immune receptor family of
Nod-like receptors (NLRs). The NLR member NLRP3 and
the adapter protein ASC form a multimolecular complex
termed the NLRP3 inflammasome.15 Inflammasomes control
the activity of caspase-1 that cleaves and activates the pro-
form of inflammatory cytokines IL-1b and IL-18. He
demonstrated that crystal uptake by cells that leads to
lysosomal damage and rupture can activate the NLRP3
inflammasome in a process that requires phagocytosis. These
results indicate that the NLRP3 inflammasome can sense
lysosomal damage as an endogenous danger signal, repre-
senting a novel strategy of immune cells to recognize different
classes of harmful stimuli by a common mechanism.16
Dr Hans-Joachim Anders (University of Munich, Germany)
discussed the role of TLRs in renal inflammation.17 Signs
of renal inflammation are observed in many of the so-called
noninflammatory kidney diseases, for example diabetic
nephropathy. TLR research might provide an explanation
for this finding, as TLR-mediated activation of the innate
immune system can be induced by both pathogen-derived
and nonpathogen-derived immunostimulatory molecules.
Thus, metabolic, hemodynamic, toxic, or autoimmune forms
of tissue damage can all trigger an innate inflammatory
response. As immune activation is unable to eliminate the
underlying drivers of nonpathogen-associated diseases, it
merely leads to unwanted aggravation of renal damage.18 The
fact that genetic variants in danger-signaling genes of the
innate immune system can affect the individual risk for
insufficient pathogen control or exaggerated nonpathogen-
related renal tissue pathology underlines the importance of
these findings for human disease.
Dr Caroline Savage (University of Birmingham, UK)
discussed the critical role of neutrophils in inflammatory
renal disease with a special focus on antineutrophil cyto-
plasmatic antibody (ANCA)-associated vasculitis. She
described new insights into the mechanisms by which
cytokine-primed neutrophils are activated by autoantibodies,
the subsequent neutrophil–endothelial cell interaction, neu-
trophil degranulation, and cytokine production (including
IL-17), ultimately leading to endothelial and tissue damage.19
Dr Neil S. Sheerin (University of Newcastle, UK) reviewed
the current understanding of how complement activation can
mediate kidney injury and highlighted new areas in which
complement components may have important regulatory
roles. He reported that complement activation can directly
injure tubular epithelial cells, induce synthesis of proin-
flammatory and profibrotic cytokines, and thereby lead to
interstitial fibrosis and tubular atrophy.20 Furthermore, he
provided evidence that a fully functional complement system
is essential for the alloimmune response after renal
transplantation, which has important implications for
inhibitor treatment.21 Finally, he discussed the gaps in our
knowledge and the challenges we face in developing
complement therapeutics for use in the clinic.
Dr Gabriela E. Garcia (University of Denver, USA)
discussed the role of A2a adenosine receptors as modulators
of inflammation. Genetic and pharmacological evidence
support a significant, nonredundant role for both adenosine
and A2A adenosine receptors (A2AR) in protecting tissue from
acute inflammatory damage. A2AR is expressed in several
inflammatory cells including T regulatory cells. In experi-
mental anti-glomerular basement membrane glomerulone-
phritis, A2AR is expressed in macrophages (Mf) from
nephritic glomeruli and its activation reduces the degree of
kidney injury in both the acute inflammatory phase and the
chronic progressive phase of glomerulonephritis.22 The
pharmacological activation of A2AR reduces inflammation
and ischemia–reperfusion injury in the liver, spinal cord,
heart, lung, and kidney. It is considered one of the most
potent endogenous anti-inflammatory mechanisms. There-
fore, A2AR ligands, despite some remaining challenges,
represent a therapeutic strategy for several inflammatory
diseases.
ADAPTIVE IMMUNE RESPONSE: T-CELL SUBTYPES AND
CHEMOKINES
CD4þ effector T cells are important regulators of the
immune response in autoimmunity and infection. They have
originally been divided in two subsets (Th1 and Th2)
according to the cytokine expression profile.23 This dichot-
omy has been challenged in the recent years by discovery of
CD4þ FoxP3 (forkhead box P3)-expressing regulatory T cells
(Tregs) and IL-17-producing Th17 cells.24 Whereas Treg cells
have their function in preventing excessive immune responses
in inflammatory diseases, Th17 cells have been linked to the
pathogenesis of autoimmune conditions including autoim-
mune kidney disease.25 Therefore, two sessions of the ISN
Forefronts meeting were dedicated to the advances in the
field of T-cell immunology with a special focus on the role of
chemokines and their receptors in CD4þ T-cell trafficking.
Dr Ari Waisman (University of Mainz, Germany) provided
an overview of the development of the Th17 field in the
past years. The implication of Th17 cells in autoimmunity
commenced with the discovery that IL-23 is essential for
development of experimental multiple sclerosis and rheuma-
toid arthritis. The subsequent finding that IL-23 induces
differentiation of Th17 cells gave rise to the notion that not
Th1, but Th17, immune response mediates autoimmunity.
IL-17 secretion was considered to be the main driving force
in the pathogenesis of Th17-dependent autoimmunity. Dr
Waisman’s group generated mice in which T cells overexpress
IL-17, and found that this did not accelerate pathogenesis
of experimental multiple sclerosis. Conversely, mice lacking
IL-17 production were fully susceptible to this experimental
model. These findings challenge the view that IL-17 is the
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central pathogenic mechanism for autoimmune disease in the
central nervous system.26 The true effector molecule(s)
produced by Th17 remains to be identified.
Dr Richard Kitching (Monash University, Melbourne,
Australia) discussed the potential role of Th17 cells in renal
inflammation. In line with findings from experimental
models of nonrenal autoimmunity, recent studies could
demonstrate that the IL-23/Th17 axis contributes to
immune-mediated kidney damage.27–31 The Kitching group
recently demonstrated in a cell transfer system that both Th1
and Th17 cells were capable of inducing glomerular injury.30
In experimental anti-MPO-induced glomerulonephritis,
IL-17 showed at least two effects: it caused initial neutrophil
recruitment and subsequently stimulated MPO-specific
effector CD4þ T cells to cause glomerular injury.31 Also,
in nephrotoxic nephritis, IL-23-dependent Th17 cells and
their mediator IL-17 were pathogenic, by mechanisms
involving IL-17-induced production of chemokines that can
recruit monocytes into the kidney.27 These findings identify
Th17 cells as new players in glomerular disease with an
immune effector signature distinct of those from Th1 cells.
Dr Kathrin Eller (University of Innsbruck, Austria)
summarized the recent progress in mouse models employing
genetic or antibody-mediated ablation of Treg cells, as well as
their adoptive transfer, that demonstrated the central role of
these cells in glomerulonephritis. In nephrotoxic nephritis,
Treg cells exerted suppressive effects in secondary lymphatic
organs, where they limited the disease by downregulating
effector T-cell activation.32 The chemokine receptor CCR7
was crucial in guiding the Tregs to lymph node areas where
antigen presentation takes place.33 Later, it was shown that
Treg cells also infiltrated the inflamed kidney tissue and
suppressed the intrarenal immune effector phase, at that
stage of the disease dependent on migration guided by the
chemokine receptor CCR6.34
Dr Ulf Panzer (University of Hamburg, Germany)
summarized the recent advances in the field of chemokine
research and their relevance for T cell-mediated glomerulo-
nephritis. In a recent study, his group demonstrated that not
only immunosuppressive Treg cells, but also pathogenic Th17
cells use the chemokine receptor CCR6 for kidney-directed
trafficking.34 Furthermore, he described the unpublished
observation that Th17 and Th1 cells sequentially infiltrate the
kidney during a nephritogenic immune response, as a
consequence of distinct chemokine receptor expression
pattern. However, the functional importance of this finding
has yet to be fully elucidated.
Dr Reinhold Fo¨rster (University of Hannover, Germany)
discussed the role of homeostatic chemokines in the
functional organization of the immune system. He provided
insight into mechanisms that induce imprinting of certain
homing properties to T cells and summarized the current
knowledge of how tissue tropism in gut-homing T cells
develops. Interestingly, stromal cells in the mesenteric lymph
nodes were recently identified as important inductors of
T-cell gut tropism in vivo.35 Whether specialized T cells with
kidney-homing properties exist is unknown and awaits
further study.
Dr Marcus Thelen (Institute for Research in Biomedicine,
Bellinzona, Switzerland) highlighted the important function
of chemokine decoy receptors in balancing the immune
response. Beside the extensively investigated scavenger
receptors D6 and DARC (Duffy antigen receptor for
chemokines) that contribute to resolution of inflammatory
processes by sequestering a large number of inflammatory
chemokines, recently, another nonsignaling receptor for the
chemokine CXCL12 (chemokine (C-X-C motif) ligand 12)
was discovered and termed CXCR7. Dr Thelen provided
details on his recent results about CXCR7 and demonstrated
that CXCR7 works as a specific and effective scavenger for
CXCL12, suggesting a critical function in modulating the
activation of the ubiquitously expressed CXCL12 receptor
CXCR4.36
ADAPTIVE IMMUNE RESPONSE: B CELLS
Dr Anja Hauser (University of Berlin, Germany) highlighted
the complex anatomical structure and spatiotemporal inter-
actions of leukocytes in germinal centers that are the cradle
of memory B and plasma cells. She introduced the utility of
multiphoton microscopy to visualize B-cell migration in
germinal centers in vivo. Her time-lapse movies revealed
the germinal center to be a highly dynamic structure and
demonstrated that functionally different B-cell subsets
display individual types of motion.37 Her presentation once
more highlighted the need to consider the kinetics of
immune responses.
Dr Oliver M. Steinmetz (University of Hamburg,
Germany) introduced a new classification of renal B-cell
infiltrates in human glomerulonephritis. B cells are regularly
present in experimental and human inflammatory kidney
disease.38,39 These infiltrates have so far been regarded as a
single entity, although in fact being quite heterogeneous.
Microanatomical analysis of renal B cells in patients with
lupus- and ANCA-associated nephritis revealed four increas-
ingly organized levels ranging from a scattered distribution to
highly compartmentalized B-cell clusters resembling second-
ary lymphoid tissue with germinal centers and follicular DC
networks.40 This new classification of B-cell infiltrates might
help to clarify contradictory findings from the past about
their clinical significance.
Dr Michael Mengel (University of Edmonton, Canada)
critically reviewed the multiple and complex roles of B cells
in renal transplant rejection. He presented studies that
correlated expression of B cell-associated transcripts
and immunoglobulin transcripts with histopathology and
function of renal allografts. Although the expression of B
cell-associated transcripts and immunoglobulin transcripts
correlated with renal function, this relationship was because
of differences in early vs late biopsies and neither B cell-
associated transcripts nor immunoglobulin transcripts were
related to allograft function after correcting for time.41
Furthermore, his microarray analyses revealed that areas with
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interstitial fibrosis and tubular atrophy are associated with a
distinctive pattern of inflammatory molecules, including B
cell/immunoglobulin- and mast cell-associated genes, which
correlated with poor outcomes.42 Dr Mengel also presented
functional studies of renal transplantation in mice, showing
that the absence of B cells in the recipient has no influence on
early rejection of allografts, but in contrast on long-term
maintenance of the inflammatory response. Thus, onset of
chronic injury is dependent on the presence of B cells.
Dr Reinhard E. Voll (University of Erlangen, Germany)
discussed the role of plasma cell depletion as a novel
therapeutic strategy for systemic lupus erythematosus. His
group demonstrated that treatment with the proteasome
inhibitor bortezomib depleted plasma cells in NZB/W F1
(New Zealand Black/White F1) lupus-prone mice including
the pathogenic anti-double-stranded DNA-producing subset.
In bortezomib-treated mice, development of lupus nephritis
was prevented and survival was dramatically prolonged. Even
when bortezomib treatment was started at later time points
with well-established lupus nephritis, proteinuria resolved
and treated mice survived significantly longer.43 Hence, as
Dr Voll explained, proteasome inhibition may represent
a novel therapeutic strategy for autoantibody-mediated
diseases including systemic lupus.
Dr Peter Heeringa (University of Groningen, The Nether-
lands) provided an overview about the role of antibodies in
ANCA-associated forms of rapidly progressive crescentic
glomerulonephritis. ANCAs comprise a group of autoanti-
bodies directed against lysosomal enzymes contained in
neutrophils and monocytes that are associated with small-
vessel vasculitides. Based on clinical and in vitro experimental
evidence, a pathogenic role for these autoantibodies has long
been suspected in ANCA-associated glomerulonephritis.44
However, to study the complex interplay between ANCAs,
neutrophils, and the local environment, animal models are
required. Here, Dr Heeringa presented the animal models
developed for ANCA glomerulonephritis and discussed how
these models have been applied to study the autoanti-
body-mediated effector mechanisms. Finally, Dr Heeringa
proposed directions for future research regarding un-
resolved issues relevant for the pathogenesis of ANCA
glomerulonephritis.45
IMPLICATIONS FOR HUMAN INFLAMMATORY RENAL DISEASE
Dr William G. Couser (University of Seattle, USA) summar-
ized the state-of-the-art knowledge of the development of
membranous glomerulonephritis, data that were primarily
obtained from experiments in the animal model of passive
Heymann nephritis.46,47 These studies lay ground to the
landmark observations recently made in human membra-
nous nephropathy.48 Salant’s group found that 70% of
patients with primary membranous nephropathy have
circulating autoantibodies against the M-type phospholipase
A2 receptor. In the kidney, this receptor is exclusively
expressed on glomerular podocytes. By immunofluorescence
it was shown that the autoantibodies, which primarily belong
to the IgG4 subclass, bind to podocytes. Although not
formally proven, the data suggest that the autoantibodies
after binding to podocytes may bind and activate comple-
ment and initiate disease. These findings are of great clinical
importance as they may eventually allow separating primary
from secondary membranous nephropathy. Furthermore,
serum autoantibody levels may help guide therapy.
Dr Renate Kain (University of Vienna, Austria) discussed
the role of lysosomal membrane glycoprotein 2 (LAMP-2) in
ANCA-associated vasculitis. The Vienna group recently
discovered autoantibodies to human LAMP-2 as antigenic
targets in patients with ANCA-associated pauci-immune
focal necrotizing glomerulonephritis (FNGN).49 Dr Kain
provided evidence for their prevalence and pathogenetic role.
Specifically, she showed that: (1) circulating anti-LAMP-2
antibodies can be detected in almost all patients presenting
with ANCA-associated FNGN; (2) antibodies to LAMP-2
cause pauci-immune FNGN when injected into rats; and
(3) a monoclonal anti-hLAMP-2 antibody induces apoptosis
of human microvascular endothelium in vitro. Furthermore,
peptide mapping identified two common human LAMP-2
epitopes in the patients’ anti-LAMP-2 autoantibodies and
one (P4149) was 100% homologous to the bacterial adhesin
FimH. Binding studies showed that the patients’ anti-P4149
autoantibodies crossreact with FimH. As infections with
fimbriated pathogens can often be observed before the onset
of FNGN, the exposure to FimH may provide a biomimicry
that allows the development of an autoimmune to LAMP-2
that may mediate the development of pauci-immune
FNGN.49
Richard J. Johnson (Denver, CO, USA) presented evidence
that minimal change disease might be mediated by the
expression of the DC-associated antigen CD80 (also known
as B7.1). Studies by Reiser et al.50 had previously shown that
TLR ligands, such as lipopolysaccharide, can induce the
expression of CD80 in podocytes in mice, resulting in actin
rearrangement and proteinuria. CD80 is normally expressed
by DCs and has an important role in T-cell activation. For a
long time, minimal change disease had been thought to be a
T-cell disorder, and some evidence from animal models
suggested that it may involve podocyte expression of CD80.51
Consistent with these experimental studies, Garin et al.52
were recently able to show that corticosteroid-sensitive
minimal change disease is associated with both glomerular
podocyte expression of CD80 and increased urinary excretion
of CD80.Unpublished experimental studies suggest that
CD80 might be induced in podocytes both in vitro and
in vivo by various TLR ligands to TLR3 and TLR4. Further
studies to identify the factors both inducing and causing the
persistent expression of CD80 in the podocytes of patients
with minimal change disease are ongoing.
CONCLUSION
ISN Forefronts Symposia have been designed to advance
scientific nephrology and familiarize nephrologists with
emerging fields in basic research that have a fundamental
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impact on the understanding, diagnosis, and treatment of
renal diseases. In perfect line with these aims, the 2010 ISN
Forefronts Symposia ‘Induction and Resolution of Renal
Inflammation’ on the secluded island of Sylt allowed the 100
participants to review current knowledge, to discuss latest
developments and new concepts in the field of inflammation,
and to provide a setting for an in-depth look into exciting
ideas that are changing the way we look at renal care.
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